Aytu Biopharma (AYTU) Convertible Debt (2015 - 2016)

Aytu Biopharma (AYTU) posted quarterly Convertible Debt of $9797.0 for Q1 2016, down 99.8% quarter-over-quarter from $4.9 million in Q4 2015.

Aytu Biopharma (AYTU) Convertible Debt (2015 - 2016) Analysis & Trends

Aytu Biopharma (AYTU) has reported Convertible Debt for 2 consecutive years, with $9797.0 the latest figure, recorded in Q1 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-
10	Aytu Biopharma	24.70 Mn	-2.01 Mn	7.60 Mn

Download Data